Why the study?
LV remodelling after STEMI worsens outcomes, but the effect of sex on post-infarct remodelling remains unknown in the contemporary era of primary PCI and optimal pharmacotherapy.
In STEMI patients treated with primary PCI and optimal pharmacotherapy, the incidence of left ventricular remodelling and its lack of impact on long-term survival are similar between men and women.
Answers are grounded in this paper and cite their sources.
LV remodelling occurs equally without survival impact in men and women post-STEMI; leaves open its prognostic role in contemporary cohorts.
AIMS: Left ventricular (LV) remodelling after ST-segment elevation myocardial infarction (STEMI) worsens outcome. The effect of sex on LV post-infarct remodelling is unknown. We therefore investigated the sex distribution and long-term prognosis of LV post-infarct remodelling after STEMI in the contemporary era of primary percutaneous coronary intervention (PCI) and optimal pharmacotherapy. METHODS AND RESULTS: Data were obtained from an ongoing primary PCI STEMI registry. LV remodelling was defined as ≥20% increase in LV end-diastolic volume at either 3, 6, or 12 months post-infarct, and LV remodelling impact on outcome was evaluated with a log-rank test. A total population of 1995 STEMI patients were analysed (mean age 60 ± 12 years): 1527 (77%) men and 468 (23%) women. The mean age of male patients was 60±11 versus 63±13 years for women (P < 0.001). A total of 953 (48%) patients experienced LV remodelling in the first 12 months of follow-up, and it was equally frequent amongst men (n = 729, 48%) and women (n = 224, 48%). After a median follow-up of 94 (interquartile range 69-119) months, 225 patients died: 171 (11%) men and 54 (12%) women. No survival difference was seen between remodellers and non-remodellers in the male (P = 0.113) and female (P = 0.920) groups. CONCLUSION: LV post-infarct remodelling incidence, as well as long-term survival of LV remodellers and non-remodellers, was similar in men and women who were treated with primary PCI and optimal pharmacotherapy post-STEMI.
No takes yet. Share an insight, caveat, or question.
Bijl et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: